Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. (DNPUF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Sumitomo Pharma Co., Ltd. (DNPUF), covering cash flow, earnings, and balance sheets.
Sumitomo Pharma Co., Ltd. (DNPUF) Income Statement & Financial Overview
View the income breakdown for Sumitomo Pharma Co., Ltd. DNPUF across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $105.65B | $112.43B | $90.07B | $90.67B |
| Cost of Revenue | $39.67B | $41.44B | $37.38B | $34.95B |
| Gross Profit | $65.98B | $71.00B | $52.70B | $55.73B |
| Gross Profit Ratio | $0.62 | $0.63 | $0.59 | $0.61 |
| R&D Expenses | $13.13B | $10.47B | $13.15B | $13.12B |
| SG&A Expenses | $49.56B | $41.04B | $44.64B | $45.36B |
| Operating Expenses | $62.69B | $49.59B | $57.79B | $58.83B |
| Total Costs & Expenses | $102.36B | $91.03B | $95.16B | $93.78B |
| Interest Income | $0.00 | $15.64B | $0.00 | $22.33B |
| Interest Expense | $7.45B | $0.00 | $23.41B | $2.02B |
| Depreciation & Amortization | $5.81B | $6.07B | $6.78B | $6.91B |
| EBITDA | $22.29B | $27.47B | -$19.42B | $26.14B |
| EBITDA Ratio | $0.21 | $0.24 | -$0.22 | $0.29 |
| Operating Income | $3.29B | $21.41B | -$5.09B | -$3.10B |
| Operating Income Ratio | $0.03 | $0.19 | -$0.06 | -$0.03 |
| Other Income/Expenses (Net) | -$9.70B | $35.03B | -$44.52B | $20.31B |
| Income Before Tax | -$6.42B | $56.43B | -$49.61B | $17.20B |
| Income Before Tax Ratio | -$0.06 | $0.50 | -$0.55 | $0.19 |
| Income Tax Expense | -$8.83B | $2.98B | -$1.45B | $1.27B |
| Net Income | $2.42B | $53.45B | -$48.17B | $15.94B |
| Net Income Ratio | $0.02 | $0.48 | -$0.53 | $0.18 |
| EPS | $6.08 | $134.53 | -$121.24 | $40.11 |
| Diluted EPS | $6.08 | $134.53 | -$121.24 | $40.11 |
| Weighted Avg Shares Outstanding | $397.29M | $397.29M | $397.29M | $397.29M |
| Weighted Avg Shares Outstanding (Diluted) | $397.29M | $397.29M | $397.29M | $397.29M |
Over the last four quarters, Sumitomo Pharma Co., Ltd. achieved steady financial progress, growing revenue from $90.67B in Q1 2024 to $105.65B in Q4 2024. Gross profit stayed firm with margins at 62% in Q4 2024 versus 61% in Q1 2024. Operating income totaled $3.29B in Q4 2024, maintaining a 3% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $22.29B. Net income dropped to $2.42B, with EPS at $6.08. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan